DENVER, December 18, 2018 – MJardin Group, Inc. (“MJardin” or the “Company”) (CSE:MJAR), a leader in cannabis management, today announced its first medical cannabis research investment to fund two studies on the benefits of cannabinoids on epilepsy and schizophrenia.
Beginning in the first quarter of 2019, the studies will be conducted in Salamanca, Spain for a period of one year, in collaboration with Salamanca University and the Institute of Neuroscience of Castilla y León – two of the leading institutions globally for the scientific research of the nervous system and its diseases.
The research will focus on the effects of cannabidiol (CBD) on epilepsy and schizophrenia and will be led by Dr. Dolores López, Ph.D. and Dr. Manuel S. Malmierca, M.D., both of whom are experts in neurodegenerative diseases and world renowned for their research on the effect of cannabinoids on neurological health.
Christine Halef, BSc Pharm, RPh., SVP, Medical Strategy for MJardin, and Dr. Ashley Masri, ND, Medical Director for MJardin, will oversee the research for MJardin.
Halef founded AtlantiCann Medical Inc. and her background as a pharmacist provides a patient-focused perspective on providing alternative treatment options to conditions that commonly afflict communities across Canada.
Dr. Masri holds a postgraduate degree in Naturopathic Medicine from the Canadian College of Naturopathic Medicine and leverages her scientific background and experience working with natural health products in patient care to coordinate MJardin’s medical research efforts.
“There is a lot of work to be done from pre-clinical to clinical trials, to better understand the medical benefits of cannabis on serious neurological disorders such as epilepsy and schizophrenia,” said Dr. Masri. “Spain is a recognized hub for medical cannabis research and we are very pleased to have the opportunity to collaborate with Salamanca University and the Institute of Neuroscience of Castilla y León to address this research gap and identify opportunities to improve the lives of millions globally.”
Dr. Dolores López, Research Full Professor at the University of Salamanca and Director of the Audiomotor Disorder’s Lab at the Neuroscience Institute of Castilla y Leon, commented, “The collaboration agreement between MJardin and the University of Salamanca opens up a great opportunity to transfer university knowledge to society, setting up the possibility of new treatments for epilepsy and schizophrenia. This research project will provide guidance on safety, dosage and efficacy of cannabidiol-based drugs, and will allow us to increase the visibility of our research within the scientific community.”
MJardin will leverage the research to guide the focus of the Company’s medical cannabis division, including the development of new products to treat a range of neurological conditions and disorders. Following completion of the studies, MJardin anticipates engaging with the appropriate regulatory bodies to begin research and testing of its products in Canada.
As the leaders of MJardin’s medical cannabis division, Halef and Dr. Masri will focus on developing strategic R&D partnerships with reputable research organizations to ensure reliability and safety of medicinal products to both physicians and patients.
“We are proud to provide financial support for this critical research while also attracting and convening a global coalition of experts to advance medical cannabis research, deepen the industry’s understanding of medical cannabis, ensure safe and effective patient care, and grow MJardin’s medical division,” added Rishi Gautam, Chairman and Chief Executive Officer of MJardin.
About MJardin Group
MJardin is a global cannabis management platform with extensive experience in cultivation, processing, distribution and retail. For over 10 years, MJardin has refined cultivation methodologies, developed state of the art facilities and implemented vertical integration for and on behalf of license owners. As a well-capitalized organization, MJardin continues to pursue strategic expansion and M&A opportunities across global legal cannabis markets. MJardin is based in Denver Colorado, with offices in Toronto, Canada and Barcelona, Spain. For more information, please visit www.mjardin.com
Capital Markets & Investor Relations
Frank Knuettel II, 720-613-4019
Chief Strategy Officer
The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
This news release contains forward-looking information based on current expectations. Statements about, among other things, future developments and the business and operations of MJardin, the medical studies discussed in this press release, the growth of or global footprint and our intentions to leverage our scale for continued organic growth and to pursue strategic investments are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such factors include, but are not limited to: our ability to identify and pursue growth, financing and other strategic objectives, and the regulatory and economic environments in the jurisdictions we operate or intend to operate or investment in. Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that the proposed acquisition will occur and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. MJardin assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.